To include your compound in the COVID-19 Resource Center, submit it here.

Roche's Gazyva gets FDA Priority Review for untreated lymphoma

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said FDA accepted and granted Priority

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE